CD19 and cancer: This data allowed the authors to conclude that B43-PAP could be safely administered in combination with VPLD reinduction chemotherapy to children with CD19+ ALL, and they announced that this would form the basis of the rationale to add B43-PAP to one of the treatment arms of a new children’s cancer group protocol for a cohort of newly diagnosed high risk paediatric cases of CD19+ ALL.